β2-Adrenergic Receptor-Mediated Histamine H1 Receptor Down-Regulation: Another Possible Advantage of β2 Agonists in Asthmatic Therapy

Journal of Pharmacological Sciences

Volumn 94, Issue 4, 2004, Pages 449-458

  Kawakami, Nozomi ^a   Miyoshi, Katsuhiro ^a   Horio, Shuhei ^a   Fukui, Hiroyuki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Asthma; Heterologous down regulation; Histamine H1 receptor; 2 adrenergic receptor; 2 receptor agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; ISOPRENALINE; KT 5720; PHOSPHOTRANSFERASE;

AIRWAY CONSTRICTION; AIRWAY RESISTANCE; ANIMAL CELL; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; NONHUMAN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SECOND MESSENGER;

EID: 2342483132     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.94.449     Document Type: Article

References (22)

1. Sibley DR, Benovic JL, Caron MG, Lefkowitz RJ. Regulation of transmembrane signaling by receptor phosphorylation. Cell. 1987;48:913-922.
2. 2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem. 2003;278:12729-12736.
3. 2-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol. 1999;56:813-823.
4. Lefkowitz RJ. G Protein-coupled receptor kinases. Cell. 1993; 74:409-412.
5. 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci USA. 1994;91:2699-2702.
6. Rim J, Oprian DD. Constitutive activation of opsin. Interaction of mutants with rhodopsin kinase and arrestin. Biochemistry. 1995;34:11938-11941.
7. Smyth EM, Li WH, Fitzgerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase C. J Biol Chem. 1998;273:23258-23266.
8. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med. 1995;152:838-860.
9. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax. 1993;48:134-138.
10. 2-agonist treatment. Am Rev Respir Dis. 1993;148:707-712.
11. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med. 1994;149:604-610.
12. Barrett TE, Strom BL. Inhaled β-adrenergic agonists in asthma: More harm than good? Am J Respir Crit Care Med. 1995; 151:574-577.
13. Chand N, Sofia RD. Histamine, in Airway Smooth Muscle. In: Raeburn D, Giembycz MA, editors. Neurotransmitters, amines, lipid mediators and signal transduction. Basel, Switzerland: Brikhauser Verlag; 1995. p. 131-155.
14. Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. 1995;16:304-309.
15. Meade CJ, Dumont I, Worrall L. Why do asthmatic subjects respond so strongly to inhaled adenosine? Life Sci. 2001;69:1225-1240.
16. Elis JL, Undem BJ. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med. 1994;149:118-122.
17. Haaksma EE, Leurs R, Timmerman H. Histamine receptors: subclasses and specific ligands. Pharmacol Ther. 1990;47:73-104.
18. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev. 1990; 42:45-83.
19. 194. Biochem Biophys Res Commun. 1994;203:1096-1101.
20. Kase H, Iwahashi K, Nakanishi S, et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun. 1987;142:436-440.
21. Mandyam CD, Thakker DR, Standifer KM. μ-Opioid-induced desensitization of opioid receptor-like 1 and μ-opioid receptors: Differential intracellular signaling determines receptor sensitivity. J Pharmacol Exp Ther. 2003;306:965-972.
22. 2-adrenoceptor activation. Mol Pharmacol. 2000;57:857-864.